• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Cytokinetics, Incorporated - Common Stock (NQ:CYTK)

    65.03 -0.29 (-0.45%)
    Streaming Delayed Price Updated: 11:17 AM EDT, Apr 27, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 298,293
    Open 65.41
    Bid (Size) 65.01 (300)
    Ask (Size) 65.04 (200)
    Prev. Close 65.32
    Today's Range 64.55 - 65.87
    52wk Range 29.31 - 70.98
    Shares Outstanding 95,640,600
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Cytokinetics Inc. (NASDAQ:CYTK) Scores Strong Setup Quality for a Potential Breakout ↗
    Via Chartmill
    News headline image
    Biohaven Stock Down 70% but One Fund's New $6 Million Bet Signals Turnaround Potential ↗
    This clinical-stage biotech focuses on developing therapies for neurological and immunoscience disorders. 
    Via The Motley Fool
    Topics Regulatory Compliance

    Performance

    YTD
    +5.3%
    +5.3%
    1 Month
    +4.0%
    +4.0%
    3 Month
    +2.9%
    +2.9%
    6 Month
    +8.1%
    +8.1%
    1 Year
    +57.8%
    +57.8%

    More News

    Read More
    News headline image
    This Biotech Stock Winner Is Up 72%, but a $4 Million Trim Signals a Slight Reset ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    This $6.5 Million Healthcare Trim Comes Amid a 71% Stock Surge and 20% Revenue Growth ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    Cytokinetics Inc (NASDAQ:CYTK) Reports Strong Q4 Revenue Beat Amid Deepening Losses and Negative Market Reaction ↗
    Via Chartmill
    CYTOKINETICS INC (NASDAQ:CYTK) Shows Strong Technicals and High-Quality Breakout Setup ↗
    Via Chartmill
    News headline image
    This $8.9 Million Buy Targets a Stock Down 68% With $322 Million in Cash ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    DAFNA Capital Trims iShares Biotechnology ETF Within Broader Biotech Portfolio, According to Recent SEC Filing ↗
    Via The Motley Fool
    Topics Derivatives ETFs Regulatory Compliance
    News headline image
    This $91 Million Position Signals Conviction in a Biotech Stock Eyeing FDA Decision This Year ↗
    Via The Motley Fool
    News headline image
    Cytokinetics Insider Exercises Options Worth Over $920,000 as Heart Drug Hits the Market ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Cytokinetics (CYTK) Q4 2025 Earnings Transcript ↗
    Via The Motley Fool
    News headline image
    European Commission Grants Marketing Authorization to Cytokinetics for Cardiac Drug MYQORZO
    Via MarketMinute
    Topics Intellectual Property
    News headline image
    Cytokinetics Secures Triple Crown: EU Approval of MYQORZO Solidifies Global Reach in Cardiovascular Market
    Via MarketMinute
    News headline image
    The Law Offices of Frank R. Cruz Announces Investigation of Cytokinetics, Incorporated (CYTK) on Behalf of Investors
    From The Law Offices of Frank R. Cruz
    Via Business Wire
    News headline image
    Important Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Lifecore Biomedical, Inc. (NASDAQ: LFCR); Molina Healthcare, Inc. (NYSE: MOH); and Synopsys, Inc. (NASDAQ: SNPS): Grabar Law Office Investigates Claims on Your Behalf
    From Grabar Law Office
    Via GlobeNewswire
    News headline image
    The $5.1 Trillion Wave: Why 2026 is Set to Become the Biggest Year for Global M&A
    Via MarketMinute
    Topics Artificial Intelligence Economy
    News headline image
    Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Lifecore Biomedical, Inc. (NASDAQ: LFCR); Molina Healthcare, Inc. (NYSE: MOH); and WEBTOON Entertainment, Inc. (NASDAQ: WBTN): Grabar Law Office Investigates Claims on Your Behalf
    From Grabar Law Office
    Via GlobeNewswire
    News headline image
    The Great Rebalancing: Small-Caps Surge as Big Tech Giants Stumble in Early 2026
    Via MarketMinute
    Topics Artificial Intelligence ETFs Economy
    News headline image
    Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Lifecore Biomedical, Inc. (NASDAQ: LFCR); Molina Healthcare, Inc. (NYSE: MOH); and WEBTOON Entertainment, Inc. (NASDAQ: WBTN): Grabar Law Office Investigates Claims on Your Behalf
    From Grabar Law Office
    Via GlobeNewswire
    News headline image
    Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026
    Via MarketMinute
    Topics Artificial Intelligence ETFs Economy
    News headline image
    Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Molina Healthcare, Inc. (NYSE: MOH); Synopsys, Inc. (NASDAQ: SNPS); and WEBTOON Entertainment, Inc. (NASDAQ: WBTN): Grabar Law Office Investigates Claims on Your Behalf
    From Grabar Law Office
    Via GlobeNewswire
    News headline image
    Notice to Long-Term Shareholders of Alexandria Real Estate Equities, Inc. (NYSE: ARE); Cytokinetics, Inc. (NASDAQ: CYTK); Molina Healthcare, Inc. (NYSE: MOH); and WEBTOON Entertainment, Inc. (NASDAQ: WBTN): Grabar Law Office Investigates Claims on Your
    From Grabar Law Office
    Via GlobeNewswire
    News headline image
    Attention Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Holley Inc. (NYSE: HLLY); Molina Healthcare, Inc. (NYSE: MOH); and WEBTOON Entertainment, Inc. (NASDAQ: WBTN): Grabar Law Office Investigates Claims on Your Behalf
    From Grabar Law Office
    Via GlobeNewswire
    News headline image
    Cytokinetics Wins First FDA Approval For Heart Disease Drug — Why Is Wall Street Still Cautious? ↗
    Via Stocktwits
    News headline image
    This Cytokinetics Director Sold 5,000 Shares in November. Is It Time to Dump the Biopharmaceutical Stock? ↗
    Via The Motley Fool
    Topics Regulatory Compliance

    Frequently Asked Questions

    Is Cytokinetics, Incorporated - Common Stock publicly traded?
    Yes, Cytokinetics, Incorporated - Common Stock is publicly traded.
    What exchange does Cytokinetics, Incorporated - Common Stock trade on?
    Cytokinetics, Incorporated - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Cytokinetics, Incorporated - Common Stock?
    The ticker symbol for Cytokinetics, Incorporated - Common Stock is CYTK on the Nasdaq Stock Market
    What is the current price of Cytokinetics, Incorporated - Common Stock?
    The current price of Cytokinetics, Incorporated - Common Stock is 65.03
    When was Cytokinetics, Incorporated - Common Stock last traded?
    The last trade of Cytokinetics, Incorporated - Common Stock was at 04/27/26 11:17 AM ET
    What is the market capitalization of Cytokinetics, Incorporated - Common Stock?
    The market capitalization of Cytokinetics, Incorporated - Common Stock is 6.22B
    How many shares of Cytokinetics, Incorporated - Common Stock are outstanding?
    Cytokinetics, Incorporated - Common Stock has 6B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.